Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients

NeuroImage

Volumn 56, Issue 1, 2011, Pages 45-51

  Molina, Vicente ^a,d   Papiol, Sergi ^b,d   Sanz, Javier ^c,d   Rosa, Araceli ^b,d   Arias, Bárbara ^b,d   Fatjó Vilas, Mar ^b,d   Calama, Julia ^a   Hernández, Ana I ^a   Bécker, Joemir ^a   Fañanás, Lourdes ^b,d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHOLINE; CREATINE; FLUORODEOXYGLUCOSE F 18; N ACETYLASPARTIC ACID; PROLINE; PROTEIN P53;

ADULT; ARTICLE; ATTENTION; BRAIN METABOLISM; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; GENE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; TP53 GENE; WHITE MATTER;

ADULT; BRAIN MAPPING; FEMALE; FRONTAL LOBE; GENOTYPE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; SCHIZOPHRENIA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953054744     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.01.076     Document Type: Article

References (56)

1. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
2. Andreasen N.C., Rajarethinam R., Cizadlo T., Arndt S., Swayze V.W., Flashman L.A., O'Leary D.S., Ehrhardt J.C., Yuh W.T. Automatic atlas-based volume estimation of human brain regions from MR images. J. Comput. Assist. Tomogr. 1996, 20:98-106.
3. Andreone N., Tansella M., Cerini R., Versace A., Rambaldelli G., Perlini C., Dusi N., Pelizza L., Balestrieri M., Barbui C., Nose M., Gasparini A., Brambilla P. Cortical white-matter microstructure in schizophrenia. Diffusion imaging study. Br. J. Psychiatry 2007, 191:113-119.
4. Ashburner J., Friston K. Multimodal image coregistration and partitioning-a unified framework. Neuroimage 1997, 6:209-217.
5. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
6. Billon N., Terrinoni A., Jolicoeur C., McCarthy A., Richardson W.D., Melino G., Raff M. Roles for p53 and p73 during oligodendrocyte development. Development 2004, 131:1211-1220.
7. Bonini P., Cicconi S., Cardinale A., Vitale C., Serafino A.L., Ciotti M.T., Marlier L.N. Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription-independent way to die. J. Neurosci. Res. 2004, 75:83-95.
8. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann. NY Acad. Sci. 1987, 508:333-348.
9. Braff D.L., Freedman R., Schork N.J., Gottesman I.I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 2007, 33:21-32.
10. Carter C.J. eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia?. Schizophr. Bull. 2007, 33:1343-1353.
11. Chiu H.J., Wang Y.C., Chen J.Y., Hong C.J., Tsai S.J. Association study of the p53-gene Pro72Arg polymorphism in schizophrenia. Psychiatry Res. 2001, 105:279-283.
12. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., Buxbaum J., Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003, 60:443-456.
13. Desco M., Pascau J., Reig S., Gispert J.D., Santos A., Benito B., Molina V., Garcia-Barreno P. Multimodality image quantification using Talairach grid. Proc. SPIE Med. Imaging 2001, 4432:1385-1392.
14. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33:357-365.
15. Ellison-Wright I., Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res. 2009, 108:3-10.
16. Frackowiak R., Friston K., Frith C., Dolan R., Mazziotta J. Human Brain Function 1997, Academic Press, San Diego.
17. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
18. Hof P.R., Haroutunian V., Friedrich V.L., Byne W., Buitron C., Perl D.P., Davis K.L. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 2003, 53:1075-1085.
19. Hoistad M., Segal D., Takahashi N., Sakurai T., Buxbaum J.D., Hof P.R. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front. Neuroanat. 2009, 3:9.
20. Kates W.R., Warsofsky I.S., Patwardhan A., Abrams M.T., Liu A.M., Naidu S., Kaufmann W.E., Reiss A.L. Automated Talairach atlas-based parcellation and measurement of cerebral lobes in children. Psychiatry Res. 1999, 91:11-30.
21. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
22. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., Jolesz F.A., Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 2007, 41:15-30.
23. Lichtenstein P., Yip B.H., Bjork C., Pawitan Y., Cannon T.D., Sullivan P.F., Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
24. Lung F.W., Shu B.C., Kao W.T., Chen C.N., Ku Y.C., Tzeng D.S. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Med. Genet. 2009, 10:147.
25. Mathalon D.H., Sullivan E.V., Lim K.O., Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 2001, 58:148-157.
26. McDonald C., Bullmore E., Sham P., Chitnis X., Suckling J., MacCabe J., Walshe M., Murray R.M. Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br. J. Psychiatry 2005, 186:369-377.
27. Minzenberg M.J., Laird A.R., Thelen S., Carter C.S., Glahn D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 2009, 66:811-822.
28. Mitelman S.A., Shihabuddin L., Brickman A.M., Hazlett E.A., Buchsbaum M.S. MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. Am. J. Psychiatry 2003, 160:2154-2168.
29. Mitkus S.N., Hyde T.M., Vakkalanka R., Kolachana B., Weinberger D.R., Kleinman J.E., Lipska B.K. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophr. Res. 2008, 98:129-138.
30. Molina V., Reig S., Sarramea F., Sanz J., Francisco Artaloytia J., Luque R., Aragues M., Pascau J., Benito C., Palomo T., Desco M. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 2003, 124:153-161.
31. Molina V., Sanz J., Sarramea F., Misiego J.M., Benito C., Palomo T. Association between excessive frontal cerebrospinal fluid and illness duration in males but not in females with schizophrenia. Eur. Psychiatry 2005, 20:332-338.
32. Molina V., Sanz J., Sarramea F., Luque R., Benito C., Palomo T. No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia. Neuropsychobiology 2006, 54:171-178.
33. Nave K.A., Trapp B.D. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci. 2008, 31:535-561.
34. Ni X., Trakalo J., Valente J., Azevedo M.H., Pato M.T., Pato C.N., Kennedy J.L. Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control and family studies. Neurosci. Lett. 2005, 388:173-178.
35. Osorio A., Martinez-Delgado B., Pollan M., Cuadros M., Urioste M., Torrenteras C., Melchor L., Diez O., De La Hoya M., Velasco E., Gonzalez-Sarmiento R., Caldes T., Alonso C., Benitez J. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum. Mutat. 2006, 27:242-248.
36. Papiol S., Arias B., Barrantes-Vidal N., Guitart M., Salgado P., Catalan R., Fananas L. Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits. Neurosci. Lett. 2004, 363:78-80.
37. Pfefferbaum A., Lim K.O., Zipursky R.B., Mathalon D.H., Rosenbloom M.J., Lane B., Ha C.N., Sullivan E.V. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. Alcohol. Clin. Exp. Res. 1992, 16:1078-1089.
38. Pomarol-Clotet E., Canales-Rodriguez E.J., Salvador R., Sarro S., Gomar J.J., Vila F., Ortiz-Gil J., Iturria-Medina Y., Capdevila A., McKenna P.J. Medial prefrontal cortex pathology in schizophrenia as revealed by convergent findings from multimodal imaging. Mol. Psychiatry 2010, 15:823-830.
39. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
40. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 1995, 52:805-818. discussion 819-820.
41. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
42. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
43. Stephan K.E., Baldeweg T., Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 2006, 59:929-939.
44. Tabares-Seisdedos R., Rubenstein J.L. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol. Psychiatry 2009, 14:563-589.
45. Talairach J., Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain 1988, Thieme Medical, New York.
46. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 1999, 19:1092-1100.
47. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., Rachmanova V. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001, 55:597-610.
48. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
49. van Haren N.E., Bakker S.C., Kahn R.S. Genes and structural brain imaging in schizophrenia. Curr. Opin. Psychiatry 2008, 21:161-167.
50. Vanhamme L., van den Boogaart A., Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 1997, 129:35-43.
51. Vazquez A., Bond E.E., Levine A.J., Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7:979-987.
52. Vos M., Adams C.H., Victor T.C., van Helden P.D. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet. Cytogenet. 2003, 140:23-30.
53. Weinberger D.R., Berman K.F., Suddath R., Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am. J. Psychiatry 1992, 149:890-897.
54. White T., Magnotta V.A., Bockholt H.J., Williams S., Wallace S., Ehrlich S., Mueller B.A., Ho B.C., Jung R.E., Clark V.P., Lauriello J., Bustillo J.R., Schulz S.C., Gollub R.L., Andreasen N.C., Calhoun V.D., Lim K.O. Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study. Schizophr. Bull. 2009, 37:222-232.
55. Woods R.P., Mazziotta J.C., Cherry S.R. MRI-PET registration with automated algorithm. J. Comput. Assist. Tomogr. 1993, 17:536-546.
56. Wosik K., Antel J., Kuhlmann T., Bruck W., Massie B., Nalbantoglu J. Oligodendrocyte injury in multiple sclerosis: a role for p53. J. Neurochem. 2003, 85:635-644.